Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:08:35 EDT Mon 14 Oct 2024
Enter Symbol
or Name
USA
CA



Q:VRDN - VIRIDIAN THERAPEUTICS INC - https://www.viridiantherapeutics.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VRDN - Q0.223.50·23.510.123.50-0.13-0.6293.56,5346,17323.57  24.08  23.3424.75  10.92515:48:00Sep 1115 min RT 2¢

Recent Trades - Last 10 of 6173
Time ETExPriceChangeVolume
15:48:06Q23.5186-0.111416
15:48:04Q23.5715-0.058510
15:48:01Q23.5184-0.11168
15:48:00Q23.5184-0.11168
15:48:00Q23.505-0.1251
15:47:55Q23.505-0.1255
15:47:54Q23.5617-0.0683100
15:47:51Q23.50-0.13100
15:47:50Q23.5258-0.10423
15:47:48Q23.5258-0.104219

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-09-11 23:25U:VRDNNews ReleaseViridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
2024-09-10 16:01U:VRDNNews ReleaseViridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
2024-09-10 07:00U:VRDNNews ReleaseViridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
2024-09-09 16:01U:VRDNNews ReleaseViridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
2024-09-05 16:01U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-08 08:15U:VRDNNews ReleaseViridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
2024-08-07 16:01U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-07-25 08:00U:VRDNNews ReleaseViridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
2024-07-03 08:00U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-06-11 06:00U:VRDNNews ReleaseViridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
2024-06-06 16:01U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-31 08:00U:VRDNNews ReleaseViridian Therapeutics Announces Participation in Upcoming June Investor Conferences
2024-05-10 08:00U:VRDNNews ReleaseViridian Therapeutics to Participate in Upcoming May Investor Conferences
2024-05-08 07:00U:VRDNNews ReleaseViridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
2024-05-03 08:00U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-29 08:00U:VRDNNews ReleaseViridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
2024-04-04 16:01U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-06 16:01U:VRDNNews ReleaseViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-05 08:00U:VRDNNews ReleaseViridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
2024-02-27 16:01U:VRDNNews ReleaseViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results